from web site
For general details, Learn more about Clinical Studies. Design table for eligibility details Ages Qualified for Research Study: 18 Years to 80 Years (Grownup, Older Adult )Sexes Qualified for Study: All Accepts Healthy Volunteers: No Addition Criteria: Solid sophisticated deadly tumors Age between18 and 80 years Life span is greater than three months Exemption Criteria: Benign growth Life span is less than 3 months Serious medical comorbidity Others Go to For more information about this study, you or your doctor might contact the research study research personnel using the contact information offered by the sponsor. gov identifier( NCT number ): Design table for location info The 2nd Affiliated Healthcare Facility of Guangzhou Medical University Guangzhou, Guangdong, China, 510260 Contact: Zhenfeng Zhang, MD, Ph, D +862039195966 zhangzhf@gzhmu. edu.cn Contact: Bingjia He, MD +862039195965 464677938@qq. com 2nd Affiliated Health Center of Guangzhou Medical University Guangdong Zhaotai In
, Vivo Biomedicine Co. Design table for detective details Principal Detective: Zhenfeng Zhang, MD, Ph, D 2nd Affiliated Health Center of Guangzhou Medical University Go to Design table for additonal information Responsible Celebration: Second Affiliated Healthcare Facility of Guangzhou Medical University Medical, Trials. gov Identifier: Other Study ID Numbers: Cp, G-ODN on tumors First Published: July 7, 2021 Secret Record Dates Last Update Published: July 7, 2021 Last Verified: June 2021 Individual Participant Data( IPD )Sharing Statement: Strategy to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Device Item: No Additional pertinent Me, SH terms: Layout table for Me, SH terms Carcinoma, Hepatocellular, Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Liver Neoplasms, Digestion System Neoplasms Neoplasms by Website, Digestion System Illness, Liver Diseases, CPG-oligonucleotide, Adjuvants, Immunologic, Immunologic Factors, Physiological Results of Drugs. For this factor, they are constantly used along with other tests. In breast cancer care, 3 growth markers-- cancer antigen 15-3( CA 15-3), cancer antigen 27. 29( CA 27. 29 ), and carcinoembryonic antigen( CEA)-- have been used to assist keep track of metastatic breast cancer( advanced disease), but they have not been found to be helpful to discover a breast cancer reoccurrence or lengthen lives in clients who had early-stage breast cancer and who are now disease-free.